参苓白术散治疗溃疡性结肠炎长期应用的疗效与安全性

Long-Term Efficacy and Safety of Shenling Baizhu Powder Treating Ulcerative Colitis

目的:探寻参苓白术散加减治疗脾虚型溃疡性结肠炎的长期临床疗效与安全性。方法:将于辽宁省人民医院2013年8月—2014年3月住院的52例溃疡性结肠炎患者随机分为治疗组26例和对照组26例。治疗组口服参苓白术散加减,对照组口服美莎拉嗪,观察两组患者口服药物半年、12个月、2年临床疗效、电子结肠镜疗效、不良反应发生情况。运用SPSS 16.0统计学软件进行统计分析。结果:治疗组在临床疗效、肠镜下肠黏膜变化、不良反应发生方面明显优于对照组。结论:参苓白术散加减治疗脾虚型溃疡性结肠炎长期应用临床疗效显著,无不良反应,适宜临床推广。

Objective： To explore the long-term clinical efficacy and safety of Shenling Baizhu Powder to treat ulcerative colitis. Methods： In Liaoning Provincial People＇s Hospital from August 2013 to March 2014,52 cases of hospitalized patients with ulcerative colitis were randomly divided into treatment group 26 cases and control group 26 cases. Treatment group was treated Shenling Baizhu Powder and the control group with the Mesalazine. Patients were observed the clinical efficacy of 6 months,12 months,two years,electronic colonoscopy efficacy and adverse events. SPSS16. 0 statistical software was used for statistical analysis. Results： Treatment group＇s clinical efficacy,endoscopic mucosal changes and adverse events were superior to those of the control group. Conclusion： Shenling Baishu Powder treating ulcerative colitis has significant long-term clinical effect and no adverse reactions,suitable for clinical practice.